The evidence has moved beyond the original version of this comparison. There is now a randomized obesity trial comparing tirzepatide with semaglutide, published phase 3 obesity evidence for retatrutide, and a completed cardiovascular outcomes trial of tirzepatide.[1][2][3] These studies answer different questions; receptor count and separate headline percentages do not establish a universal ranking.

Read the results by population, comparator and endpoint. A weight-loss comparison, a placebo-controlled trial and a cardiovascular noninferiority trial are different kinds of evidence.

Correction, October 17, 2026: The original version said retatrutide had never been tested past phase 2, that direct tirzepatide-versus-semaglutide evidence was limited to diabetes, and that only semaglutide had a completed cardiovascular outcomes trial. These statements and their summary copies have been corrected. The checked trial abstracts do not support a universal drug ranking. This is a scoped update; full clinical review remains pending.

One receptor, two, three

Each compound adds a receptor to the one before it, and the additions are not decoration.

  • Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class.[4] One receptor.
  • Tirzepatide is a dual agonist at the GIP and GLP-1 receptors, characterised by Thomas and colleagues in work on beta-cell function and insulin sensitivity.[5] Two.
  • Retatrutide is a triple hormone receptor agonist, adding the glucagon receptor to those two.[6] Three.

The third receptor is the interesting one, and it works differently from the other two. GLP-1 and GIP agonism act largely on appetite and insulin. Glucagon receptor agonism acts on the other side of the ledger: in a randomized study, combined GLP-1 and glucagon receptor agonism was associated with less of the drop in energy expenditure that normally accompanies weight loss.[7]

That mechanistic finding does not establish that receptor count ranks these three medicines by clinical efficacy.

Weight reduction: separate historical trials and a direct comparison

The following are historical examples from separate obesity or overweight trials, retained for context rather than as a current head-to-head ranking:

  • Semaglutide 2.4 mg weekly: mean body weight fell about 15 percent at week 68, against about 2.4 percent on placebo, in the trial reported by Wilding and colleagues.[8]
  • Tirzepatide: mean body weight fell about 21 percent at the highest dose at week 72, reported by Jastreboff and colleagues.[9]
  • Retatrutide: mean body weight fell about 24 percent at the highest dose at week 48, in a phase 2 trial.[6]

Historical weight-reduction results from separate trials

  • Semaglutide 2.4 mg, 68 weeks: 15
  • Tirzepatide, 72 weeks: 21
  • Retatrutide, 48 weeks: 24

Background examples with different populations and durations, including an earlier retatrutide phase 2 result. Not a direct three-drug comparison; later evidence is discussed below.

The chart combines separate trials with different durations and populations. Its bar heights cannot establish which of the three medicines is superior. The direct comparison below answers a more specific question.

SURMOUNT-5 directly compared tirzepatide with semaglutide in 751 adults with obesity without type 2 diabetes. This phase 3b randomized, open-label trial used once-weekly subcutaneous treatment for 72 weeks. Mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide. That is direct evidence for this trial population and weight endpoint; retatrutide was not part of the comparison.[1]

Safety: what the measured endpoints can establish

A shared pattern of adverse events does not establish equal safety across medicines or populations.

Gastrointestinal effects dominate. In the tolerability analysis of once-weekly semaglutide 2.4 mg, nausea, vomiting and diarrhoea were the common events, mostly mild to moderate and transient.[10] The same pattern appears in the tirzepatide and retatrutide trials, and it scales with dose.

The cited heart-rate meta-analysis searched through July 31, 2025 and measured change in heart rate. That is a different endpoint from clinical cardiovascular events, and its search predates the later retatrutide phase 3 publication.[11]

Retatrutide is no longer characterized only by one phase 2 study. TRIUMPH-1 randomized 2,339 adults with obesity without diabetes and followed them for 80 weeks. Its publication adds phase 3 evidence, but does not by itself establish a cardiovascular safety ranking against the other two medicines.[2]

The question nobody wants asked: what happens when you stop

The cited semaglutide extension addresses withdrawal after that medicine, rather than a randomized withdrawal comparison of all three.

In the extension of the semaglutide weight-management trial, participants regained most of the lost weight within a year of withdrawal, and the cardiometabolic improvements reverted with it.[12]

most of the lost weight regained within a year of stopping semaglutide PMID 35441470

This result should not be generalized to tirzepatide or retatrutide solely from the semaglutide extension. Treatment duration, follow-up and the withdrawal study design matter.

The comparison that separates them

Cardiovascular studies need their own population and comparator context. The claim that only semaglutide has a completed cardiovascular outcomes trial is outdated.

Lincoff and colleagues ran a cardiovascular outcome trial in adults with overweight or obesity and established cardiovascular disease but without diabetes, and once-weekly semaglutide reduced major adverse cardiovascular events against placebo.[13]

SURPASS-CVOT compared tirzepatide with dulaglutide in people with type 2 diabetes and atherosclerotic cardiovascular disease. It met noninferiority for cardiovascular death, myocardial infarction or stroke; superiority was not established. This active-comparator result in diabetes answers a different question from SELECT's placebo-controlled result without diabetes.[3][13]

Match the question to the trial

For cardiovascular outcomes, keep SELECT and SURPASS-CVOT separate. They studied different populations and controls, so their results do not create a simple ranking of these medicines.[13][3]

For weight reduction without diabetes, SURMOUNT-5 supplies a direct tirzepatide-versus-semaglutide comparison. Its open-label design and specific endpoint remain part of the interpretation.[1]

For retatrutide, the phase 3 obesity publication is available. TRIUMPH-1 used a placebo comparator, rather than either of the other two medicines.[2] Trial evidence and regulatory approval are separate: FDA currently identifies retatrutide as unapproved.

There is no single ranking supported by lining up receptor counts or percentages from separate trials. Use the study population, comparator, measured endpoint and evidence limits to understand each result.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.

References

  1. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine, 2025.
  2. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine, 2026.
  3. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine, 2025.
  4. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.. Annals of internal medicine, 2025.
  5. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.. The Journal of clinical endocrinology and metabolism, 2021.
  6. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.. The New England journal of medicine, 2023.
  7. Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial.. Obesity (Silver Spring, Md.), 2023.
  8. Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 2021.
  9. Tirzepatide Once Weekly for the Treatment of Obesity.. The New England journal of medicine, 2022.
  10. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.. Diabetes, obesity & metabolism, 2022.
  11. Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.. European journal of medical research, 2026.
  12. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.. Diabetes, obesity & metabolism, 2022.
  13. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.. The New England journal of medicine, 2023.